The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from May 31st through June 4th, 2019. This year’s conference was highly varied, with key data presented for drugs in numerous different classes and indications. Highlights included new data for Kisqali in HR+/HER2- breast cancer, Xtandi in prostate cancer, Lynparza in pancreatic cancer, and AMG510 in KRAS mutation-positive solid tumors. As with the past several years, PD-1/PD-L1 inhibitors were also featured prominently, with products like Keytruda, Opdivo, and Tecentriq each being included in multiple presentations. CAR-T therapies also remained in the spotlight, with this year’s conference showing their future potential in solid tumor indications.

This post-meeting report features commentary from our analysts on key presentations given at the conference as well as a compilation of all data events added to Biomedtracker in conjunction with the meeting.

For the full report, download the PDF version at the top of the page. A full list of ASCO events is also available for download as an Excel file.

To view Scrip's ASCO coverage, please refer to this landing page- Scrip ASCO Coverage.

For our disclosures, please read the Biomedtracker Research Standards.